Interleukin-11, an interleukin-6-like cytokine, is a promising predictor for bladder cancer prognosis

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 684-688

  Wu, Deyao ^a   Tao, Jun ^b   Ding, Jingjing ^c   Qu, Ping ^a   Lu, Qiang ^b   Zhang, Wei ^b  

^a NANTONG MEDICAL COLLEGE   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bladder cancer; Interleukin 11; Prognosis

Indexed keywords

INTERLEUKIN 11; INTERLEUKIN 6;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RECEPTOR DOWN REGULATION; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-11; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84873819636     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1199     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL and Ries LA: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116: 544-573, 2010.
3. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, Sesterhenn IA, Tachibana M and Weider J: Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66: 4-34, 2005.
4. Heney NM: Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 19: 429-433, 1992.
5. Bellmunt J and Guix M: New agents for bladder cancer. Ann Oncol 21 (Suppl 7): vii56-58, 2010.
6. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, vanderMeijden A, Parmar MK and Bijnens L: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156: 1934-1940, 1996.
7. Sylvester RJ, Oosterlinck W and van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171: 2186-2190, quiz 2435, 2004.
8. Sengupta S and Blute ML: The management of superficial transitional cell carcinoma of the bladder. Urology 67: 48-54, 2006.
9. Dovedi SJ and Davies BR: Emerging targeted therapies for bladder cancer: a disease waiting for a drug. Cancer Metastasis Rev 28: 355-367, 2009.
10. Teramura M, Kobayashi S, Yoshinaga K, Iwabe K and Mizoguchi H: Effect of interleukin 11 on normal and pathological thrombopoiesis. Cancer Chemother Pharmacol 38: S99-S102, 1996.
11. von Rango U, Alfer J, Kertschanska S, Kemp B, Muller-Newen G, Heinrich PC, Beier HM and Classen-Linke I: Interleukin-11 expression: its significance in eutopic and ectopic human implantation. Mol Hum Reprod 10: 783-792, 2004.
12. McKinley D, Wu Q, Yang-Feng T and Yang YC: Genomic sequence and chromosomal location of human interleukin-11 gene (IL11). Genomics 13: 814-819, 1992.
13. Grosfeld JL, Du X and Williams DA: Interleukin-11: its biology and prospects for clinical use. JPEN J Parenter Enteral Nutr 23: S67-S69, 1999.
14. Yap J, Salamonsen LA, Jobling T, Nicholls PK and Dimitriadis E: Interleukin 11 is upregulated in uterine lavage and endometrial cancer cells in women with endometrial carcinoma. Reprod Biol Endocrinol 8: 63, 2010.
15. Furuya Y, Nishio R, Junicho A, Nagakawa O and Fuse H: Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer. Int Urol Nephrol 37: 69-71, 2005.
16. Sales KJ, Grant V, Cook IH, Maldonado-Perez D, Anderson RA, Williams AR and Jabbour HN: Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F2alpha-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. Am J Pathol 176: 435-445, 2010.
17. Nakayama T, Yoshizaki A, Izumida S, Suehiro T, Miura S, Uemura T, Yakata Y, Shichijo K, Yamashita S and Sekin I: Expression of interleukin-11 (IL-11) and IL-11 receptor α in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells. Int J Oncol 30: 825-833, 2007.
18. Trepicchio WL and Dorner AJ: Interleukin-11. A gp130 cytokine. Ann NY Acad Sci 856: 12-21, 1998.
19. Du XX and Williams DA: Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood 83: 2023-2030, 1994.
20. Weich NS, Wang A, Fitzgerald M, Neben TY, Donaldson D, Giannotti J, Yetz-Aldape J, Leven RM and Turner KJ: Recombinant human interleukin-11 directly promotes megakaryocytopoiesis invitro. Blood 90: 3893-3902, 1997.
21. Du X, Everett ET, Wang G, Lee WH, Yang Z and Williams DA: Murine interleukin-11 (IL-11) is expressed at high levels in the hippocampus and expression is developmentally regulated in the testis. J Cell Physiol 168: 362-372, 1996.
22. Musashi M, Yang YC, Paul SR, Clark SC, Sudo T and Ogawa M: Direct and synergistic effects of interleukin 11 on murine hemopoiesis in culture. Proc Natl Acad Sci USA 88: 765-769, 1991.
23. Musashi M, Clark SC, Sudo T, Urdal DL and Ogawa M: Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice. Blood 78: 1448-1451, 1991.
24. Holyoake TL, Freshney MG, McNair L, Parker AN, McKay PJ, Steward WP, Fitzsimons E, Graham GJ and Pragnell IB: Exvivo expansion with stem cell factor and interleukin-11 augments both short-term recovery posttransplant and the ability to serially transplant marrow. Blood 87: 4589-4595, 1996.
25. Yin TG, Schendel P and Yang YC: Enhancement of in vitro and in vivo antigen-specific antibody responses by interleukin 11. J Exp Med 175: 211-216, 1992.
26. Elias JA, Tang W and Horowitz MC: Cytokine and hormonal stimulation of human osteosarcoma interleukin-11 production. Endocrinology 136: 489-498, 1995.
27. Trepicchio WL, Bozza M, Pedneault G and Dorner AJ: Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 157: 3627-3634, 1996.
28. Kapina MA, Shepelkova GS, Avdeenko VG, Guseva AN, Kondratieva TK, Evstifeev VV and Apt AS: Interleukin-11 drives early lung inflammation during Mycobacterium tuberculosis infection in genetically susceptible mice. PLoS One 6: e21878.
29. Sonis S, Muska A, O'Brien J, Van Vugt A, Langer-Safer P and Keith J: Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur J Cancer B Oral Oncol 31B: 261-266, 1995.
30. Du X, Liu Q, Yang Z, Orazi A, Rescorla FJ, Grosfeld JL and Williams DA: Protective effects of interleukin-11 in a murine model of ischemic bowel necrosis. Am J Physiol 272: G545-G552, 1997.
31. Castagliuolo I, Kelly CP, Qiu BS, Nikulasson ST, LaMont JT and Pothoulakis C: IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am J Physiol 273: G333-G341, 1997.
32. Zheng T, Zhu Z, Wang J, Homer RJ and Elias JA: IL-11: insights in asthma from overexpression transgenic modeling. J Allergy Clin Immunol 108: 489-496, 2001.
33. Waxman AB, Einarsson O, Seres T, Knickelbein RG, Warshaw JB, Johnston R, Homer RJ and Elias JA: Targeted lung expression of interleukin-11 enhances murine tolerance of 100% oxygen and diminishes hyperoxia-induced DNA fragmentation. J Clin Invest 101: 1970-1982, 1998.
34. Putoczki T and Ernst M: More than a sidekick: the IL-6 family cytokine IL-11 links inflammation to cancer. J Leukoc Biol 88: 1109-1117, 2010.
35. Michaud DS: Chronic inflammation and bladder cancer. Urol Oncol 25: 260-268, 2007.
36. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
37. Hussain SP, Hofseth LJ and Harris CC: Radical causes of cancer. Nat Rev Cancer 3: 276-285, 2003.
38. Ohshima H, Tatemichi M and Sawa T: Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys 417: 3-11, 2003.
39. Klaunig JE and Kamendulis LM: The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44: 239-267, 2004.
40. Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA and Weiss RM: Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol 161: 630-634, 1999.
41. Egner JR: AJCC Cancer Staging Manual. JAMA 304: 1726-1727, 2010.
42. Bartsch G, Mitra AP and Cote RJ: Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Rev Anticancer Ther 10: 1945-1954, 2010.